442
Participants
Start Date
May 31, 2015
Primary Completion Date
October 12, 2018
Study Completion Date
October 12, 2018
Lurbinectedin (PM01183)
Pegylated liposomal doxorubicin (PLD)
Topotecan
1112, Peoria
1102, Greenbrae
1103, La Jolla
1116, Los Angeles
1120, Los Angeles
1113, Palo Alto
1111, San Francisco
1122, Santa Maria
1123, West Hills
1109, Augusta
1104, Indianapolis
1110, Covington
1124, Scarborough
1121, Brick
1127, Albany
1105, New York
1117, Asheville
1101, Charlotte
1125, Charlotte
1108, Durham
1107, Columbus
1118, Dayton
1119, Pittsburgh
1115, Greenville
1129, Nashville
1131, Fort Worth
1128, Houston
1106, Charlottesville
Lead Sponsor
PharmaMar
INDUSTRY